The stock market showed continued weakness on Tuesday with all of the major indexes down for the session as inflation fears remained a key concern. However, the Nasdaq’s recovery from an intraday 2% pullback into positive territory was a slight silver-lining.It remains to been seen if the recovery off the lows was a temporary head fake but we will find out quickly with Wednesday’s update on...
Continue reading >>Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...
Continue reading >>The stock market showed continued weakness on Tuesday with all of the major indexes down for the session as inflation fears remained a key concern. However, the Nasdaq’s recovery from an intraday 2% pullback into positive territory was a slight silver-lining.It remains to been seen if the recovery off the lows was a temporary head fake but we will find out quickly with Wednesday’s update on...
Continue reading >>...
Continue reading >>The stock market showed continued weakness on Tuesday with all of the major indexes down for the session as inflation fears remained a key concern. However, the Nasdaq’s recovery from an intraday 2% pullback into positive territory was a slight silver-lining.It remains to been seen if the recovery off the lows was a temporary head fake but we will find out quickly with Wednesday’s update on...
Continue reading >>Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...
Continue reading >>